[131I]meta-Iodobenzylguanidine and Topotecan Combination Treatment of Tumors Expressing the Noradrenaline Transporter
- 1 November 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 11 (21) , 7929-7937
Abstract
Purpose: Both [131I]meta-iodobenzylguanidine ([131I]MIBG) and the topoisomerase I inhibitor topotecan are effective as single-agent treatments of neuroblastoma. The aim of this study was to investigate the efficacy of [131I]MIBG in combination with topotecan in vitro and in vivo.Keywords
This publication has 39 references indexed in Scilit:
- A phase I study of Topotecan, as a radiosensitizer, for thoracic malignanciesLung Cancer, 2004
- Efficacy of Topotecan and Cyclophosphamide Given in a Phase II Window Trial in Children With Newly Diagnosed Metastatic Rhabdomyosarcoma: A Children’s Oncology Group StudyJournal of Clinical Oncology, 2004
- Cellular and Molecular Responses to Topoisomerase I Poisons: Exploiting Synergy for Improved RadiotherapyAnnals of the New York Academy of Sciences, 2000
- Dose-response relationship for radiation-induced mutations at micro- and minisatellite loci in human somatic cells in cultureInternational Journal of Radiation Biology, 2000
- Topotecan in Pediatric Patients With Recurrent and Progressive Solid TumorsJournal of Pediatric Hematology/Oncology, 1998
- Radiolabelled mIBG in the treatment of neuroblastomaEuropean Journal of Cancer, 1996
- Pharmacokinetics and efficacy of 131I-meta-iodobenzylguanidine in two neuroblastoma xenograftsBritish Journal of Radiology, 1994
- N-myc gene copy number in neuroblastoma cell lines and resistance to experimental treatmentEuropean Journal of Cancer, 1994
- Interaction of topoisomerase I inhibitors with radiation in cis‐diamminedichloroplatinum(II)‐sensitive and ‐resistantcells In Vitro and in the fsaiic fibrosarcoma In VivoInternational Journal of Cancer, 1993
- Detection of Etoposide Resistance by Measuring DNA Damage in Individual Chinese Hamster CellsJNCI: Journal of the National Cancer Institute, 1990